Search

everythinglearnresearchcommunity

for

Search:↓

A manager told an employee to stop using minoxidil, fearing it could unintentionally cause hair growth in others. The conversation is filled with humorous and sarcastic responses, questioning the manager's logic and suggesting the employee continue using the treatment secretly.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

AB-103, a minoxidil sulfotransferase stimulant, is discussed as a potential hair loss treatment. Users inquire about effective boosters for hair growth.

The user is attempting to regrow hair using natural methods like microneedling, rosemary oil, and capsaicin tincture, avoiding medications like finasteride and minoxidil due to past health issues. Feedback suggests these methods are ineffective, with many recommending shaving or considering a hair system instead.

There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.

Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. User skepticism is expressed about the effectiveness of these treatments.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Alternative treatments for hair loss such as Procapil, Redensyl, and Baicapil being compared to Minoxidil, Finasteride, and RU58841.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

The product being promoted is likely ineffective for hair regrowth, as it lacks key ingredients like minoxidil and finasteride, and may rely on deceptive marketing tactics such as lighting tricks. Users suggest that proven treatments like minoxidil and finasteride are more reliable for hair loss.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The user experienced hair regrowth and stabilization at Norwood 2 using natural remedies like pumpkin seed oil, rosemary oil, vitamins, and scalp massages, avoiding minoxidil and finasteride due to side effects. Another user suggested starting topical finasteride earlier to prevent further hair loss.

The conversation discusses the potential benefits of adding Vitamin B6 (P-5-P) to topical hair loss treatments like RU58841, finasteride, or minoxidil. The user suggests that Vitamin B6 might enhance these treatments by naturally lowering scalp prolactin.